BDBM50371521 EZETIMIBE
BDBM50240720 ezetimibe-glucuronide (2S,3S,4S,5R,6S)-6-(4-((2S,3R)-1-(4-fluorophenyl)-3-((S)-3-(4-fluorophenyl)-3-hydroxypropyl)-4-oxoazetidin-2-yl)phenoxy)-3,4,5-trihydroxy-tetrahydro-2H-pyran-2-carboxylic acid (2S,3S,4S,5R,6S)-6-(4-{(2S,3R)-1-(4-Fluoro-phenyl)-3-[(S)-3-(4-fluoro-phenyl)-3-hydroxy-propyl]-4-oxo-azetidin-2-yl}-phenoxy)-3,4,5-trihydroxy-tetrahydro-pyran-2-carboxylic acid (2S,3S,4S,5R,6S)-6-(4-{(2S,3R)-1-(4-Fluoro-phenyl)-3-[3-((S)-4-fluoro-phenyl)-3-hydroxy-propyl]-4-oxo-azetidin-2-yl}-phenoxy)-3,4,5-trihydroxy-tetrahydro-pyran-2-carboxylic acid CHEMBL321017
- Alméciga-Diaz, CJ; Hidalgo, OA; Olarte-Avellaneda, S; Rodríguez-López, A; Guzman, E; Garzón, R; Pimentel-Vera, LN; Puentes-Tellez, MA; Rojas-Rodriguez, AF; Gorshkov, K; Li, R; Zheng, W Identification of Ezetimibe and Pranlukast as Pharmacological Chaperones for the Treatment of the Rare Disease Mucopolysaccharidosis Type IVA. J Med Chem 62: 6175-6189 (2019)